Sedative hypnotic medication use and the risk of motor vehicle crash

American Journal of Public Health

Volumn 105, Issue 8, 2015, Pages e64-e69

  Hansen, Ryan N ^a   Boudreau, Denise M ^a,b   Ebel, Beth E ^a,c   Grossman, David C ^b,d   Sullivan, Sean D ^a,d  

^a UNIVERSITY OF WASHINGTON   (United States)

^b GROUP HEALTH RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d U S DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYPNOTIC SEDATIVE AGENT; PRESCRIPTION DRUG; PYRIDINE DERIVATIVE; TEMAZEPAM; TRAZODONE; ZOLPIDEM;

ADULT; EPIDEMIOLOGY; FEMALE; HUMAN; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; STATISTICS AND NUMERICAL DATA; TRAFFIC ACCIDENT; WASHINGTON;

ACCIDENTS, TRAFFIC; ADULT; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; MALE; MIDDLE AGED; PRESCRIPTION DRUGS; PROPORTIONAL HAZARDS MODELS; PYRIDINES; RISK FACTORS; TEMAZEPAM; TRAZODONE; WASHINGTON;

EID: 84934777601     PISSN: 00900036     EISSN: 15410048     Source Type: Journal    
DOI: 10.2105/AJPH.2015.302723     Document Type: Article

References (37)

1. Zammit G. Comparative tolerability of newer agents for insomnia. Drug Saf. 2009;32(9):735-748.
2. Botteman M. Health economics of insomnia therapy: implications for policy. Sleep Med. 2009;10(suppl 1):S22-S25.
3. Riemann D, Perlis ML. The treatments of chronic insomnia: a review of benzodiazepine receptor agonists and psychological and behavioral therapies. Sleep Med Rev. 2009;13(3):205-214.
4. Gunja N. The clinical and forensic toxicology of z-drugs. J Med Toxicol. 2013;9(2):155-162.
5. Paul MA, Gray G, MacLellan M, et al. Sleep-inducing pharmaceuticals: a comparison of melatonin, zaleplon, zopiclone, and temazepam. Aviat Space Environ Med. 2004;75(6):512-519.
6. Cummings P, Koepsell TD, Moffat JM, Rivara FP. Drowsiness, counter-measures to drowsiness, and the risk of a motor vehicle crash. Inj Prev. 2001;7(3):194-199.
7. Ahlm K, Bjornstigb U, Ostrom M. Alcohol and drugs in fatally and non-fatally injured motor vehicle drivers in northern Sweden. Accid Anal Prev. 2009;41(1):129-136.
8. Borkenstein RF, Crowther RP, Shumate RP, Ziel HB, Zylman R. The role of the drinking driver in traffic accidents. Bloomington, IN: Department of Police Administration, Indiana University; 1964.
9. Ray WA, Fought RL, Decker MD. Psychoactive drugs and the risk of injurious motor vehicle crashes in elderly drivers. Am J Epidemiol. 1992;136(7):873-883.
10. Hetland A, Carr DB. Medications and impaired driving. Ann Pharmacother. 2014;48(4):494-506.
11. Orriols L, Salmi LR, Philip P, et al. The impact of medicinal drugs on traffic safety: a systematic review of epidemiological studies. Pharmacoepidemiol Drug Saf. 2009;18(8):647-658.
12. FDA Drug Safety Communication. Risk of next-morning impairment after use of insomnia drugs; FDA requires lower recommended doses for certain drugs containing zolpidem (Ambien, Ambien CR, Edluar, and Zolpimist). 2013. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm334033.htm. Accessed September 9, 2014.
13. FDA Drug Safety Communication. FDA approves new label changes and dosing for zolpidem products and a recommendation to avoid driving the day after using Ambien CR. 2013. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm352085.htm. Accessed September 9, 2014.
14. Micromedex 2.0. Available at: http://www.thomsonhc.com/micromedex2. Accessed May 3, 2010.
15. Kripke DF, Langer RD, Kline LE. Hypnotics' association with mortality or cancer: a matched cohort study. BMJ Open. 2012;2(1):e000850.
16. Weich S, Pearce HL, Croft P, et al. Effect of anxiolytic and hypnotic drug prescriptions on mortality hazards: retrospective cohort study. BMJ. 2014;348:g1996.
17. Farkas RH, Unger EF, Temple R. Zolpidem and driving impairment - identifying persons at risk. N Engl J Med. 2013;369(8):689-691.
18. Chang CM, Wu EC, Chen CY, et al. Psychotropic drugs and risk of motor vehicle accidents: a population-based case-control study. Br J Clin Pharmacol. 2013;75(4):1125-1133.
19. th ed. West Sussex, England: John Wiley and Sons; 2005:223-239.
20. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613-619.
21. Gallian JA. Assigning driver's license numbers. Math Mag. 1991;64(1):13-22.
22. Boudreau DM, Yu O, Chubak J, et al. Comparative safety of cardiovascular medication use and breast cancer outcomes among women with early stage breast cancer. Breast Cancer Res Treat. 2014;144(2):405-416.
23. Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA. 1995;274(8):620-625.
24. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158(9):915-920.
25. Lin DY, Wei LJ. The robust inference for the Cox proportional hazards model. J Am Stat Assoc. 1989;84:1074-1078.
26. Barlow WE. Robust variance estimation for the case-cohort design. Biometrics. 1994;50(4):1064-1072.
27. Lin DY, Wei LJ, Ying Z. Checking the Cox model with cumulative sums of Martingale-based residuals. Biometrika. 1993;80:557-572.
28. LeRoy AA, Morse ML. Multiple medications and vehicle crashes: analysis of databases. Washington, DC: National Highway Traffic Safety Administration; 2008. DOT HS 810 858.
29. Peck RC, Gebers MA, Voas RB, Romano E. The relationship between blood alcohol concentration (BAC), age, and crash risk. J Safety Res. 2008;39(3):311-319.
30. DUI/DWI laws March 2012. Insurance Institute for Highway Safety. Available at: http://www.iihs.org/laws/dui.aspx. Accessed March 3, 2012.
31. Engeland A, Skurtveit S, Morland J. Risk of road traffic accidents associated with the prescription of drugs: a registry-based cohort study. Ann Epidemiol. 2007;17(8):597-602.
32. Leufkens TR, Vermeeren A. Highway driving in the elderly the morning after bedtime use of hypnotics: a comparison between temazepam 20 mg, zopiclone 7.5 mg, and placebo. J Clin Psychopharmacol. 2009;29(5):432-438.
33. Bezemer KDB, Smink BE, van Maanen R, Verschraagen M, de Gier JJ. Prevalence of medicinal drugs in suspected impaired drivers and a comparison with the use in the general Dutch population. Forensic Sci Int. 2014;241:203-211.
34. Gustavsen I, Bramness JG, Skurtveit S, Engeland A, Neutel I, Morland J. Road traffic accident risk related to prescriptions of the hypnotics zopiclone, zolpidem, flunitrazepam and nitrazepam. Sleep Med. 2008;9(8):818-822.
35. Partinen M, Hirvonen K, Hublin C, Halavaara M, Hiltunen H. Effects of after-midnight intake of zolpidem and temazepam on driving ability in women with non-organic insomnia. Sleep Med. 2003;4(6):553-561.
36. Suissa S. Statistical methods in pharmacoepidemiology: advances and challenges. Stat Methods Med Res. 2009;18(1):3-6.
37. Signorello LB, McLaughlin JK, Lipworth L, Friis S, Sorensen HT, Blot WJ. Confounding by indication in epidemiologic studies of commonly used analgesics. Am J Ther. 2002;9(3):199-205.